| abstract |
The disclosure includes a formulation comprising: (i) a therapeutically effective amount of at least one antibiotic; and (ii) a therapeutically effective amount of at least one probiotic material. The antibiotic includes a non-systemic gram negative antibiotic (such as, for example, fodaximicin) and the formulation is prepared in a dosage form for delivery to the gastrointestinal tract. The disclosure further includes a method of preventing or minimizing the proliferation of Clostridium difficile in the gastrointestinal tract of a mammal undergoing an antibiotic therapy comprising; methods of preventing or minimizing the occurrence of antibiotic-associated diarrhea in a mammal undergoing an antibiotic therapy; and methods of preventing or minimizing the occurrence of antibiotic-associated colitis or pseudomembranous colitis in a patient undergoing an antibiotic therapy. |